Cytokinetics (CYTK) grants 87,297 RSUs to new legal chief officer

Cytokinetics, Inc. (CYTK) reported an equity award to its Chief Legal & Admin Officer, Mr. Hessekiel.

Rhea-AI Filing Summary

Cytokinetics, Inc. (CYTK) reported an equity award to its Chief Legal & Admin Officer, Mr. Hessekiel. On 11/14/2025, he received an initial new hire grant of 87,297 restricted stock units (RSUs) of common stock at a price of $0 per share, all held as direct ownership after the transaction.

The RSUs convert into common stock on a 1:1 basis as they vest. The vesting schedule is staggered over three years: 40% of the RSUs vest one year from the grant date, another 40% vest two years from the grant date, and the remaining 20% vest three years from the grant date, in each case conditioned on his continued employment with Cytokinetics.

Insider Trade Summary

Grant/Award: 87,297 shares

Grant/Award 1 txn

Insider Hessekiel Jeffrey

Role Chief Legal & Admin Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	87,297	$0.00	$0.00

Holdings After Transaction: Common Stock — 87,297 shares (Direct)

Footnotes (1)

1. F1. Initial new hire grant comprised of restricted stock units ("RSUs") that are convertible to shares of common stock on a 1:1 basis upon vesting. RSUs will vest as follows: 40% of the aggregate RSUs on the date falling 1-year from the date of grant, an additional 40% of the aggregate RSUs on the date falling 2-years from the date of grant, and the remaining 20% of the aggregate RSUs on the date falling 3-years from the date of grant, in each case subject to Mr. Hessekiel's continued employment with Cytokinetics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cytokinetics (CYTK) disclose in this Form 4 filing?

Cytokinetics disclosed that its Chief Legal & Admin Officer, Mr. Hessekiel, received an initial new hire grant of 87,297 restricted stock units (RSUs) of common stock on 11/14/2025.

How many Cytokinetics (CYTK) shares were granted to the officer and at what price?

The officer was granted 87,297 RSUs, each convertible into one share of Cytokinetics common stock, at a grant price of $0 per share.

What is the vesting schedule for the 87,297 Cytokinetics (CYTK) RSUs?

The RSUs vest in three tranches: 40% one year from the grant date, an additional 40% two years from the grant date, and the final 20% three years from the grant date, subject to continued employment.

What role does the reporting person hold at Cytokinetics (CYTK)?

The reporting person serves as Chief Legal & Admin Officer of Cytokinetics and filed this Form 4 as an officer of the company.

How many Cytokinetics (CYTK) shares does the officer beneficially own after this transaction?

Following the reported transaction, the officer beneficially owns 87,297 shares of Cytokinetics common stock through these RSUs, held as direct ownership.

Are the Cytokinetics (CYTK) RSUs subject to any employment conditions?

Yes. Each vesting tranche of the RSUs is conditioned on Mr. Hessekiel’s continued employment with Cytokinetics through the applicable vesting dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/17/2025 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hessekiel Jeffrey

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal & Admin Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		A(1)		87,297	A	$0	87,297	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Initial new hire grant comprised of restricted stock units ("RSUs") that are convertible to shares of common stock on a 1:1 basis upon vesting. RSUs will vest as follows: 40% of the aggregate RSUs on the date falling 1-year from the date of grant, an additional 40% of the aggregate RSUs on the date falling 2-years from the date of grant, and the remaining 20% of the aggregate RSUs on the date falling 3-years from the date of grant, in each case subject to Mr. Hessekiel's continued employment with Cytokinetics.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Hessekiel	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.